Drug Profile
EPZ 015666
Alternative Names: EPZ015666; GSK3235025Latest Information Update: 22 Aug 2022
Price :
$50
*
At a glance
- Originator Epizyme
- Class Antineoplastics; Small molecules
- Mechanism of Action PRMT5 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Mantle-cell lymphoma
Most Recent Events
- 12 Aug 2022 Epizyme has been acquired by Ipsen
- 28 Jun 2019 No recent reports of development identified for preclinical development in Mantle-cell-lymphoma in USA (PO)
- 05 Dec 2017 Chemical structure information added